Join
Live feed
·
PRReleasevia Quantisnow
Eledon Pharmaceuticals Inc. logo

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

ByQuantisnow·Wall Street's wire, on your screen.
ELDN· Eledon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELDN (Eledon Pharmaceuticals Inc.) and more on Quantisnow.